{"schema_version":"1","generated_at":"2026-11-04T08:50:23.182Z","data_as_of":null,"url":"https://www.findmykol.com/kol/eugenia-girda","json_url":"https://www.findmykol.com/kol/eugenia-girda/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"eugenia-girda","name":"Eugenia Girda","credential":"MD","specialty":"Gynecologic Oncology","specialty_raw":"Gynecologic Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Rutgers","institution_url":"https://www.findmykol.com/institution/rutgers","city":"New Brunswick","state":"NJ","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1497032106","orcid":"0000-0002-4787-5475","openalex":"A5055824335"},"summary":"Eugenia Girda is an Oncology physician affiliated with Rutgers. OpenAlex indexes 127 publications with 2,194 citations (h-index 19); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":127,"cited_by_count":2194,"h_index":19,"latest_activity_year":2026,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT03428802","title":"Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","role":"Overall official","sponsor":"Rutgers, The State University of New Jersey","source_url":"https://clinicaltrials.gov/study/NCT03428802","trial_url":"https://www.findmykol.com/trial/NCT03428802"}],"source":"trials"},"payments":{"company_count":2,"program_years":{"first":2021,"last":null},"rows_total":32,"shown":3,"withheld":29,"rows":[{"payer":"Regeneron","program_year":2025,"amount_usd":459549.06,"payment_count":31,"source_url":"https://openpaymentsdata.cms.gov/search?query=1497032106"},{"payer":"Merck & Co.","program_year":2025,"amount_usd":137986.88,"payment_count":6,"source_url":"https://openpaymentsdata.cms.gov/search?query=1497032106"},{"payer":"Genentech","program_year":2025,"amount_usd":10399.8,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1497032106"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1497032106","source":"payments"},"prescribing":{"data_year":2024,"areas_total":3,"areas_shown":3,"areas":[{"area":"Nervous system","share_pct":43.7,"classes_total":2,"classes":[{"class":"Phenothiazine","setting":"prescribed","share_pct":28.2,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":null},{"class":"Opioid Agonist","setting":"prescribed","share_pct":15.5,"drugs":[{"name":"Oxycodone Hcl","share_pct":100}],"max_beneficiaries":11}]},{"area":"Cancer & immunology","share_pct":35.2,"classes_total":2,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":19.7,"drugs":[{"name":"Letrozole","share_pct":100}],"max_beneficiaries":null},{"class":"Kinase inhibitor","setting":"prescribed","share_pct":15.5,"drugs":[{"name":"Verzenio","share_pct":100}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":21.1,"classes_total":1,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":21.1,"drugs":[{"name":"Ondansetron Hcl","share_pct":100}],"max_beneficiaries":11}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5502","status":"verified"},{"title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial","year":2025,"journal":"Nature Medicine","source_url":"https://doi.org/10.1038/s41591-025-03566-1","status":"verified"},{"title":"A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors","year":2025,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1078-0432.ccr-24-4280","status":"verified"},{"title":"Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)","year":2025,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1078-0432.ccr-24-3128","status":"verified"},{"title":"Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients","year":2025,"journal":"Oncotarget","source_url":"https://doi.org/10.18632/oncotarget.28703","status":"verified"}],"source":"works"},"contact":{"address_1":"195 LITTLE ALBANY ST","city":"New Brunswick","state":"NJ","zip":"089011914","phone":"732-235-7258","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1497032106","source":"identity"},"similar":[{"name":"Reynold Panettieri","slug":"reynold-panettieri","institution":"Rutgers","specialty":"Pulmonary Disease","url":"https://www.findmykol.com/kol/reynold-panettieri","json_url":"https://www.findmykol.com/kol/reynold-panettieri/profile.json"},{"name":"Manreet Kanwar","slug":"manreet-kanwar","institution":"Rutgers","specialty":"Advanced Heart Failure and Transplant Cardiology","url":"https://www.findmykol.com/kol/manreet-kanwar","json_url":"https://www.findmykol.com/kol/manreet-kanwar/profile.json"},{"name":"Brenda Kurnik","slug":"brenda-kurnik","institution":"Rutgers","specialty":"Nephrology","url":"https://www.findmykol.com/kol/brenda-kurnik","json_url":"https://www.findmykol.com/kol/brenda-kurnik/profile.json"},{"name":"Jacob Sage","slug":"jacob-sage","institution":"Rutgers","specialty":"Neurology","url":"https://www.findmykol.com/kol/jacob-sage","json_url":"https://www.findmykol.com/kol/jacob-sage/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":29,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2024-07-12","provider_certified":"2024-06-07","collected_at":"2026-11-03T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}